Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis, Inc. (NYSE: STXS) is active in surgical robotics and medical device innovation, and its news flow reflects ongoing developments in minimally invasive endovascular intervention and cardiac electrophysiology. Company announcements frequently highlight regulatory milestones, product clearances, clinical adoption, and capital markets activity, making the STXS news page a focused resource for tracking these events in one place.
Recent news releases describe U.S. Food and Drug Administration approval of the MAGiC Magnetic Interventional Ablation Catheter, FDA 510(k) clearance for the GenesisX Robotic Magnetic Navigation system, and CE Mark in Europe for the Synchrony digital cath lab system along with a 510(k) submission to the FDA. Other updates cover the commercial launch and first procedures using the MAGiC Sweep high-density electrophysiology mapping catheter, as well as clinical use of the Genesis system at leading medical centers.
Investors and clinicians following STXS can also find news on collaborations, such as the agreement with CardioFocus to advance a robotic pulsed field ablation solution for cardiac arrhythmias. Financial and investor-relations updates, including quarterly earnings press releases and participation in healthcare and growth conferences, are regularly communicated through company news.
This page aggregates these categories of information—regulatory clearances, product launches, clinical milestones, collaborations, and financial communications—so readers can monitor how Stereotaxis’ robotic systems, catheters, and digital cath lab technologies progress over time. For anyone tracking STXS stock or the evolution of its technology portfolio, the news feed offers a structured view of the company’s publicly reported developments.
Stereotaxis (NYSE: STXS) announced it will release its 2022 first quarter financial results on May 10, 2022, before U.S. markets open. The company will host a conference call at 10 a.m. EST to discuss the results and corporate developments. Investors can access the call at 888-254-3590 (US) or 1 929-477-0448 (International) using passcode 5168103. A replay will be available for one month after the call. Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, having treated over 100,000 patients globally.
Stereotaxis (NYSE: STXS) announces that Poland's National Institute of Cardiology has launched the first robotic electrophysiology program using the Genesis Robotic Magnetic Navigation (RMN) system, enhancing cardiac arrhythmia treatment. This technology is now operational in 25 countries. A study reports that 3.8% of Warsaw residents aged 20-65 have arrhythmias, indicating over 2 million potential cases in Poland. This initiative aims to improve patient care and advance clinical science in Europe.
Stereotaxis (NYSE: STXS) has inaugurated its new 45,000-square-foot global headquarters in downtown St. Louis, located in the historic Globe Building. This state-of-the-art facility will significantly enhance its surgical robotics operations for minimally invasive endovascular interventions. The headquarters is designed for substantial long-term growth, housing R&D, advanced manufacturing, and distribution capabilities. The event featured demonstrations of their Robotic Magnetic Navigation technology, which has been utilized in over 100 hospitals worldwide.
Stereotaxis (STXS) reported its fourth quarter and full year 2021 financial results, highlighting a 32% revenue growth year-over-year, totaling $35.0 million. The fourth quarter revenue reached $8.2 million, up 21% from the prior year. System revenue saw significant gains, with $11.2 million for the year, reflecting increased adoption of its Genesis RMN systems. The company has a robust innovation pipeline and starts 2022 with $40 million in cash. However, operating losses increased to approximately ($3.4 million) in Q4, and supply chain issues affected new robotic program opportunities.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive interventions, announced that David Fischel, chairman and CEO, will present at three investor conferences in Q1 2022. The presentations include:
- BTIG Virtual Conference on February 15, 2022, at 10:30 am EST
- Aegis Capital Corp. Virtual Conference on February 25, 2022, at 12:00 pm EST
- Cowen Virtual 42nd Annual Health Care Conference on March 8, 2022, at 10:30 am EST
Fischel aims to discuss Stereotaxis' technology and growth strategy with investors.
Stereotaxis (NYSE: STXS) announced plans to release its financial results for Q4 and full year 2021 on March 3, 2022, before the market opens. The company will hold a conference call at 10 a.m. EST to discuss the results and corporate developments. Interested parties can access the call by dialing 866-409-1555 or through the investor relations section of Stereotaxis’ website. The company is a leader in surgical robotics for minimally invasive endovascular interventions, with technology used to treat over 100,000 patients globally.
Stereotaxis (NYSE: STXS) announced the establishment of a robotic electrophysiology program at Fuwai Central China Cardiovascular Hospital, marking a significant milestone as the first in central China. The initial robotic cardiac ablation procedure was successfully performed by Dr. Chen Ke and Dr. Song Weifeng, highlighting the efficiency and safety of the Robotic Magnetic Navigation technology. Hospital officials emphasized their commitment to providing advanced treatment options for arrhythmias, with expectations for future robotic-assisted interventional procedures.
Stereotaxis (NYSE: STXS) announced that HonorHealth has launched a robotic electrophysiology program at its Scottsdale Shea Medical Center, utilizing the Genesis Robotic Magnetic Navigation (RMN) system. This initiative aims to enhance patient care for those undergoing cardiac ablation procedures, vital for treating arrhythmias. Dr. Rahul Doshi emphasized the program's potential to transform care, while Dr. Maulik Shah highlighted HonorHealth's commitment to advanced medical technologies. David Fischel, CEO of Stereotaxis, expressed enthusiasm about supporting HonorHealth's vision in improving patient outcomes.
Stereotaxis (NYSE: STXS) has announced a new publication demonstrating the effectiveness of its Robotic Magnetic Navigation (RMN) technology in reducing silent cerebral embolism (SCE) during atrial fibrillation ablation procedures. A study of 166 patients found that RMN significantly decreased SCE incidence to 5.77%, compared to 32.26% with manual catheters (p<0.001). This pivotal research, conducted independently in China, could position Stereotaxis as a leader in improving patient safety in cardiac interventions, reinforcing the efficacy of robotic solutions in complex procedures.
Stereotaxis (NYSE: STXS) has announced its inaugural Innovation Day on December 13, 2021, at 4:00 p.m. EST. This live webcast event will showcase the company's innovation pipeline with presentations from leadership and a Q&A session. Stereotaxis is recognized as a global leader in surgical robotics for minimally invasive endovascular intervention, having treated over 100,000 patients worldwide. Interested participants can register in advance at www.stereotaxis.com/innovation-day.